&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-05-22, 12:00

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-05-07, 12:00

Sandoz reports first quarter 2024 sales

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-30, 17:25

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Kaitlyn Granata

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-30, 12:00

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Basil Slack

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-04-22, 12:00

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Bradley Crotty

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-03-21, 20:00

Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
Jillian Pearce

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-02-29, 13:00

Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
Kristofer Henninger

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-02-01, 13:15

Sandoz announces changes in the Board of Directors
Myrna Laughlin

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-01-31, 13:00

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-01-22, 13:00

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Popular Posts